SEC Form 4
------------

П

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1	Iress of Reporting	Person*	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [		tionship of Reporting Pe all applicable)	erson(s) to Issuer
Jones Mich		(1.1.1.1.)	BCRX ]	x	Director Officer (give title below)	10% Owner Other (specify below)
(Last) 4505 EMPER SUITE 200	(First) OR BLVD.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022		Exec. Director, Fin	nance - PAO
,			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filin	ng (Check Applicable
(Street)	NC	27703		X	Form filed by One Re	porting Person
		27703			Form filed by More the Person	an One Reporting
(City)	(State)	(Zip)				
		Table I - Non-De	rivative Securities Acquired, Disposed of, or Benef	icially	Owned	

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	03/01/2022		М		2,300	Α	\$4.73	13,498	D	
Common Stock	03/01/2022		S		2,300	D	\$17.2	11,198	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

								-			-				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deri Sec Acq (A) ( Disp of (I	oosed D) tr. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative (Instr. 3 an	f 9 Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Emp. Stock Option (Right to Buy)	\$4.73	03/01/2022		М			2,300	03/01/2013	03/01/2022	Common Stock	2,300	\$0	0	D	

Explanation of Responses:

Michael L. Jo	-
viichael L. Jo	mes

\*\* Signature of Reporting Person Date

03/03/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5